Product Name | Sorafenib; BAY 43-9006; Sorafenib Base; Sorafenib Free Base |
---|---|
CAS | 284461-73-0 |
Formula | C21H16ClF3N4O3 |
MW | 464.82 |
Appearance | White to off-white powder |
Storage condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Sorafenib (BAY549085; BAY-549085; BAY439006; BAY-439006; Nexavar; SFN) an approved anticancer medication, is a potent and orally bioavailable multikinase inhibitor with potential anticancer activity (BAY549085; BAY-549085; BAY439006; BAY-439006; Nexavar; SFN). In enzymatic assays, it inhibits numerous kinases, including Raf-1, B-Raf, and VEGFR-2, with IC50 values of 6 nM, 22 nM, and 90 nM, respectively. The FDA granted sorafenib approval in 2005 to treat advanced renal cancer.
© Copyright 2015-2021 Chemleader Biomedical Co., Ltd. All Rights Reserved.
沪ICP备15046197号-4
沪公网安备31011502007856号
Designed by Kuanersoft